Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 298, Issue 12, Pages 102700
Publisher
Elsevier BV
Online
2022-11-14
DOI
10.1016/j.jbc.2022.102700
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer
- (2022) Fengyi Mao et al. PROSTATE
- Triggering a switch from basal- to luminal-like breast cancer subtype by the small-molecule diptoindonesin G via induction of GABARAPL1
- (2020) Minmin Fan et al. Cell Death & Disease
- Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
- (2019) Jane Guan et al. CELL
- Discovery of Novel Celastrol Derivatives as Hsp90–Cdc37 Interaction Disruptors with Antitumor Activity
- (2019) Na Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
- (2018) Rinath Jeselsohn et al. CANCER CELL
- Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner
- (2018) Frederick Zhehao Zhang et al. Oncotarget
- Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells
- (2017) Jian Gao et al. Cell Death & Disease
- AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
- (2016) H. M. Weir et al. CANCER RESEARCH
- High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines
- (2016) Channing Yu et al. NATURE BIOTECHNOLOGY
- Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β
- (2016) Kendrick H. Yim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reciprocal Regulation of ERα and ERβ Stability and Activity by Diptoindonesin G
- (2015) Zibo Zhao et al. CHEMISTRY & BIOLOGY
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
- (2014) Michel van Kruchten et al. Cancer Discovery
- Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation
- (2013) Y Zhang et al. BRITISH JOURNAL OF CANCER
- D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
- (2013) K. Merenbakh-Lamin et al. CANCER RESEARCH
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Genome engineering using the CRISPR-Cas9 system
- (2013) F Ann Ran et al. Nature Protocols
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Phosphorylation by p38 Mitogen-Activated Protein Kinase Promotes Estrogen Receptor Turnover and Functional Activity via the SCFSkp2 Proteasomal Complex
- (2012) S. Bhatt et al. MOLECULAR AND CELLULAR BIOLOGY
- ERα Phosphorylation at Y537 by Src Triggers E6-AP-ERα Binding, ERα Ubiquitylation, Promoter Occupancy, and Target Gene Expression
- (2012) Jun Sun et al. MOLECULAR ENDOCRINOLOGY
- Withaferin A targets heat shock protein 90 in pancreatic cancer cells
- (2009) Yanke Yu et al. BIOCHEMICAL PHARMACOLOGY
- Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
- (2009) Charles Erlichman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
- (2008) Alison Donnelly et al. CURRENT MEDICINAL CHEMISTRY
- CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins
- (2008) Y. Morishima et al. HUMAN MOLECULAR GENETICS
- Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against Several Cancer Cell Lines
- (2008) Joseph A. Burlison et al. JOURNAL OF ORGANIC CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now